Concepedia
Statistics
Publications
5
Citations
356
H-Index
Active since
2014
Affiliations
Institute of Cancer Research(Current)
University of Manchester
Cancer Research UK
Cancer Research UK Manchester Institute
Robert McLeary is an author at Institute of Cancer Research specializing in molecular oncology, pharmacology, and enzyme inhibition.
Publications per year
2014–2020
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
María Romina Girotti, Filipa M. Lopes, Natasha Preece et al. · Cancer Cell · 2014 · 209 citations · Full text
Medicine, Cancer Biology, Oncology +17
Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure–Activity Relationships
Leo Leung, Dan Niculescu‐Duvaz, Deborah A. Smithen et al. · Journal of Medicinal Chemistry · 2019 · 70 citations · Full text
Pharmacy, Medicinal Chemistry, Pharmacology +15
2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth
Deborah A. Smithen, Leo Leung, Mairi Challinor et al. · Journal of Medicinal Chemistry · 2019 · 45 citations · Full text
Medicine, Medicinal Chemistry, Pharmacology +13
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
G. Saturno, Filipa M. Lopes, Ion Niculescu‐Duvaz et al. · Annals of Oncology · 2020 · 21 citations · Full text
Medicine, Oncology, Pharmacology +17
Design and discovery of 3-aryl-5-substituted-isoquinolin-1-ones as potent tankyrase inhibitors
Richard Elliott, Ashley Jarvis, Mohan B. Rajasekaran et al. · MedChemComm · 2015 · 11 citations
Pharmacy, Medicinal Chemistry, Pharmacology +13
1–5 of 5